Phase II trial of CH5424802 (alectinib hydrochloride) for recurrent or refractory ALK-positive anaplastic large cell lymphoma: Study protocol for a non-randomized non-controlled trial
Hirokazu Nagai, Reiji Fukano, Masahiro Sekimizu, Akiko Kada, Akiko M. Saito, Ryuta Asada, Tetsuya Mori
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Phase II trial of CH5424802 (alectinib hydrochloride) for recurrent or refractory ALK-positive anaplastic large cell lymphoma: Study protocol for a non-randomized non-controlled trial'. Together they form a unique fingerprint.